Karl Spector, MD
Internal Medicine · Bel Air, MDNPI 1164472551
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 206 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,063, 2.4 times the $437 reported in 2019.
Across 206 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$699
- Lilly USA, LLC$444
- AstraZeneca$385
- AbbVie$321
- Pfizer$299
- Amgen$285
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,589100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 46 | $699 |
| Lilly USA, LLC | 23 | $444 |
| AstraZeneca | 21 | $385 |
| AbbVie(2 entities) | 19 | $321 |
| Pfizer | 16 | $299 |
| Amgen | 17 | $285 |
| Abbott | 8 | $170 |
| Exact Sciences | 8 | $131 |
| Almatica Pharma LLC | 4 | $94 |
| Boehringer Ingelheim | 5 | $89 |
| Indivior Inc. | 3 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $63 |
| Kowa Pharmaceuticals America, Inc. | 4 | $59 |
| Phathom Pharmaceuticals, Inc. | 3 | $55 |
| Optinose US, Inc. | 2 | $45 |
| Agios Pharmaceuticals, Inc. | 1 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $36 |
| Amarin Pharma, Inc. | 2 | $33 |
| GSK | 2 | $33 |
| Mylan Specialty L.p. | 1 | $32 |
| Braeburn Inc. | 1 | $27 |
| Merck | 2 | $25 |
| Dexcom, Inc. | 1 | $23 |
| Antares Pharma, Inc. | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Medtronic | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Nevro Corp. | 1 | $13 |
| Shire North American Group Inc | 1 | $12 |
How this compares
$3,601 in reported general payments places this provider in the 85th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 106 | $119,028 |
| TrulicityDulaglutide | 49 | $101,860 |
| OzempicSemaglutide | 58 | $73,853 |
| XareltoRivaroxaban | 34 | $44,277 |
| JardianceEmpagliflozin | 22 | $34,197 |
| RybelsusSemaglutide | 13 | $30,588 |
| FarxigaDapagliflozin Propanediol | 19 | $30,440 |
| Xigduo XrDapaglifloz Propaned/Metformin | 19 | $23,838 |
| NucyntaTapentadol Hcl | 12 | $23,080 |
| JanuviaSitagliptin Phosphate | 12 | $19,917 |
| EntrestoSacubitril/Valsartan | 11 | $17,871 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 105 | $16,516 |
| MounjaroTirzepatide | 14 | $15,684 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $15,680 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 72 | $14,662 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $299 | $119,028106 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $444 | $117,54463 claims |
| Novo NordiskOzempic, Rybelsus | $699 | $104,44071 claims |
| Boehringer IngelheimJardiance | $89 | $34,19722 claims |
| AstraZenecaFarxiga | $385 | $30,44019 claims |
| MerckJanuvia | $25 | $19,91712 claims |
| GSKBreo Ellipta | $33 | $15,68028 claims |
| AbbVieSynthroid | $321 | $4,90071 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Bel Air
- Sinnarajah RagurajBel Air$19K
- Marianne MannHighland$2.1M
- Param DedhiaBaltimore$636K
- Curtis RosebraughAshton$418K
- Mark CorriereColumbia$402K
- Gregory PokrywkaTowson$377K
- Shawn DhillonBaltimore$227K
- Brian HarveyAnnapolis$220K
- Jeremy SugarmanBaltimore$210K
- Florence HounPotomac$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.